NOVN SIX

Novartis

Follow Open structure map Ask about this Research this company

Description

NOVN · SIX

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.

Wikipedia · CC BY-SA 4.0

Headquarters: CH
Website: Website

Structure of Novartis

Novartis

Company

15 connections

OwnershipInvestment and holdings1 of 2

UpstreamSupply and dependency2 of 3

ConstraintsRegulation and exposure3 of 5

DownstreamCustomers

OwnProducts and technology2 of 3

Relationship began2026Unsorted nodes

NovartisCompany · 15 connections

Layer 1

UpstreamSupply and dependency2

DownstreamCustomers7

OwnershipInvestment and holdings1

OwnProducts and technology2

ConstraintsRegulation and exposure3

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

Novartisoperates in →Multiple sclerosis
Industry · Multiple sclerosisEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  In multiple sclerosis (MS), Novartis has helped shape the treatment landscape for decades through scientific innovation and leadership in advancing care for people living with MS.
  View source
Novartisoperates in →Neurology
Industry · NeurologyEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
  View source
Novartisoperates in →Spinal muscular atrophy
Industry · Spinal muscular atrophyEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
  View source
Novartisoperates in →Neuroimmunology
Industry · NeuroimmunologyEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
  View source
Novartisoperates in →Neurodegeneration
Industry · NeurodegenerationEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
  View source
Novartisoperates in →Neuromuscular diseases
Industry · Neuromuscular diseasesEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
  View source
Novartiscost exposure →global healthcare cost containment
Industry · global healthcare cost containmentEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment
  View source
Novartisprice exposure →pricing and reimbursement pressures
Industry · pricing and reimbursement pressuresEvidence 1
Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-07 19:00
  ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency
  View source

Showing 1 to 8 of 20

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1

acquiresChinook

No public evidence summary is available.

钛媒体 · 2026-10-09 14:53

View evidence

Media钛媒体2026-10-09 14:53
View source

FactEvidence 1

manufacturesiptacopan

No public evidence summary is available.

钛媒体 · 2026-10-09 14:53

View evidence

Media钛媒体2026-10-09 14:53
View source

FactEvidence 1

acquireszigakibart

No public evidence summary is available.

钛媒体 · 2026-10-09 14:53

View evidence

Media钛媒体2026-10-09 14:53
View source

FactEvidence 1

people reached by its medicinesmore than 300 million people

Our medicines reach more than 300 million people worldwide.

GlobeNewswire public company news · 2026-10-07 19:00

View evidence

CompanyGlobeNewswire public company news2026-10-07 19:00
Our medicines reach more than 300 million people worldwide.
View source

FactEvidence 1

price exposurepricing and reimbursement pressures

ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency

GlobeNewswire public company news · 2026-10-07 19:00

View evidence

CompanyGlobeNewswire public company news2026-10-07 19:00
ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency
View source

FactEvidence 1

cost exposureglobal healthcare cost containment

In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment

GlobeNewswire public company news · 2026-10-07 19:00

View evidence

CompanyGlobeNewswire public company news2026-10-07 19:00
In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment
View source

Showing 1 to 6 of 23

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Not available: Company signals · Financials · Filings · Guidance